Press Releases from Omnix Medical (3 total)
Omnix Medical Advances Novel Anti-Infective Program into Clinical Development
- Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR)
JERUSALEM, Israel, March 16, 2022 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy volunteers. The trial will be conducted in Groningen, The Netherlands.
OMN6, the lead compound of Omnix,…
Omnix Medical Receives NIH Grant for the Development of its Novel Antimicrobial …
-- Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB)
-- Clinical trial preparations of OMN6 under way
JERUSALEM, Israel, August 31, 2021 -- Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has received a grant by the U.S. National Institutes of Health (NIH) for the development of its first-in-class antimicrobial peptide OMN6 targeting Acinetobacter baumannii (AB). Acinetobacter baumannii are multi-drug resistant…
Omnix Medical Wins €10.8M in EIC Accelerator Funding
- Novel class of anti-infectives fighting hospital-associated infections and multi-drug resistant bacteria
- Lead program OMN6 to be advanced to proof-of-concept in humans
- Dr. Antonius Schuh appointed as Chairman of the Board of Directors
JERUSALEM, Israel, January 25, 2021 -- Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme. The award will…
Go To Page: 1
